Oxygenta Pharmaceutical (BOM:524636) Interest Expense : ₹-15.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Oxygenta Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Oxygenta Pharmaceutical's interest expense for the three months ended in Mar. 2024 was ₹ -5.9 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₹-15.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Oxygenta Pharmaceutical's Operating Income for the three months ended in Mar. 2024 was ₹ -22.8 Mil. Oxygenta Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ₹ -5.9 Mil. Oxygenta Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oxygenta Pharmaceutical Interest Expense Historical Data

The historical data trend for Oxygenta Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxygenta Pharmaceutical Interest Expense Chart

Oxygenta Pharmaceutical Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Interest Expense

Get a 7-Day Free Trial

-10.90

-17.75

-9.15

-14.88

-15.94

Oxygenta Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-9.41	-2.94	-3.41	-3.64	-5.95

Oxygenta Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-15.9 Mil.

Oxygenta Pharmaceutical (BOM:524636) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Oxygenta Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ₹-5.9 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₹-22.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₹490.0 Mil.

Oxygenta Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Oxygenta Pharmaceutical did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Oxygenta Pharmaceutical (BOM:524636) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Oxygenta Pharmaceutical Ltd (BOM:524636) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

Plot no: 43, The Park View 1st Floor, Beside Sky View Suites (Saketa Nilayam), Behind Preston Prime Mall, Lumbini Avenue, Gachibowli, Hyderabad, TG, IND, 500032

Website

http://oxygentapharma.com

Oxygenta Pharmaceutical Ltd is a pharmaceutical company. It is engaged in the business activity of manufacturing bulk drugs and API. It specializes in manufacturing anti ulcerative and anti-bacterial drugs. The Company has one reportable segment which is Pharmaceutical. The group carries its business operations within India.

Oxygenta Pharmaceutical (BOM:524636) Headlines

No Headlines